10 September 2019
New York, 10 September 2019 – Tiziana Life Sciences plc (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for inflammatory diseases and cancers, is pleased to report Phase 1 clinical data demonstrating that nasally administered...
Read more04 September 2019
THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE...
Read more06 August 2019
New York and London, August 6, 2019 – Tiziana Life Sciences plc (NASDAQ: TLSA; AIM: TILS) (the "Company" or "Tiziana"), a U.S. and U.K. biotechnology company that focuses on the discovery and development of novel molecules to treat human disease...
Read moreOur mission is to bring breakthrough therapies to patients with the aim of reversing severe liver diseases, autoimmune and inflammatory diseases and optimizing health outcomes.
Learn moreWith several candidates in the clinic, our development portfolio is supported by extensive IP and a strong pipline of in-licenced clinical and pre-clinical assets.
Milciclib is the Company’s Phase 2 clinical candidate for the treatment of multiple cancer indications such as hepatocellular carcinoma, thymic cancer and thymoma.
Learn more about MilciclibForalumab is a fully human anti-CD3 monoclonal antibody (mAb) for treatment of NASH, Crohn’ s Disease and a neurodegenerative indication.
Learn more about ForalumabWith several candidates being prepared for clinic, our development portfolio is supported by extensive IP and a strong pipline of in-licenced clinical and pre-clinical assets.
We are developing a fully human monoclonal antibody (mAb) targeting the receptor for IL-6. This asset was in-licensed from Novimmune in January 2017.
Learn more about Anti IL-6rStemPrintER is a multi-gene signature assay intended for use as a diagnostic screen in patients with estrogen-receptor positive ER+/HER2 negative breast cancers.
Learn more about StemPrintER™Tiziana is currently conducting clinical development programs for Foralumab and Milciclib
We initiated a Phase 2a trial (CDKO-125a-010) of Milciclib safety and tolerability as a single therapy in sorafenib-resistant patients with HCC in the first half of 2017.
See more Milciclib clinical trialsTiziana is currently conducting a Phase I clinical trial of nasally-dosed Foralumab in healthy subjects in collaboration with Dr. Howard Weiner at Brigham and Women’s Hospital in Boston.
See more Foralumab clinical trials
